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Chronic respiratory disorders (CRDs) concern many people and generate important health and
social costs. Their global impact (particularly that of COPD) has been the subject of numerous
pharmacoeconomic studies published in recent years. These studies confirm the growing
impact of COPD in all countries, in terms of the patient and patient’s family, and that of
society as a whole. The attitude towards COPD management is still largely inadequate, from
prevention to diagnosis to drug and non-pharmacologic long-term treatment. The pulmonary
specialist, in cooperation with other health professionals, can play a fundamental role in de-
tecting inappropriateness in the clinical course of COPD and provide the basis for a correct
assessment of pharmacoeconomic issues.
Given the increasing social impact of COPD, the meeting inspiring this review, “COPD
a social disease: inappropriateness and pharmacoeconomics. The role of the specialist:
present and future”, Venice, Italy, 21e22 April 2010, fits in perfectly with the goals and
recommendations of GARD (Global Alliance against chronic Respiratory Diseases) of the
WHO. GARD has formulated working recommendations: i) to develop national programs of
prevention and control of CRDs, starting from health education campaigns and better knowl-
edge of epidemiology, impact, and relative risk factors; ii) to provide training and continuing
education on prevention and treatment of CRDs, disseminating the existing guidelines; andence “COPD a social disease: inappropriateness and pharmacoeconomics. The role of the specialist:
ly, April 21e22, 2010, and organized by AIMAR within the ‘Year of the Lung 2010’ promoted worldwide
ory Societies and within Europe by the European Respiratory Society. AIMAR has been a partner since
ronic Respiratory Diseases (GARD) of the World Health Organisation (WHO).
22 836718/846549; fax: þ39 322 869950.
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Pharmacoeconomics in COPD 829iii) to facilitate access to essential treatments and favour adherence to long-term treatment,
including drug treatment and pulmonary rehabilitation, particularly amongst disadvantaged
sectors of the population.
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representing altogether (including lung cancer) the 2nd
major cause of mortality worldwide: given the present
degree of underdiagnosis they are probably even more
frequent than currently anticipated.1,2 The future trend
seems for a further increase, though differentiated for the
individual disorders chronic obstructive pulmonary disease
(COPD) in particular is one of the major health problems
worldwide, negatively affecting patients and their families,
the employment sector, and society. Its epidemiological,
clinical, social and socio-economic impact is on the rise and
there is no evidence of any change in these trends.3 In fact,
COPD is estimated to become the 3rd cause of death world-
wide by 2020. These figuresmake it important to identify risk
factors associated with COPD and seek early treatments as
soon as lung function impairment and symptoms emerge. At
present,most people are not diagnosed until they are in their
late 50’s when their respiratory lung function has already
started to decline in a clinically significant way.4
The high level of underdiagnosis/undertreatment or
misdiagnosis/mistreatment in the early stages of the
disease underscores the problem of inadequate standards of
care, that are a general problem even in developed coun-
tries, at all levels of intervention from limited prevention
through inappropriate long-term management.5,6Prevention
Lifestyle modifications can help prevent COPD, or improve
lung function: smoking cessation, avoidance of respiratoryirritants, prevention of infections, maintaining balanced
nutrition and hydration, avoiding extreme environmental
conditions, maintaining proper weight, and exercising to
increase muscle tone.7 However, data are insufficiently
evidence-based for some of these factors. Quite solid data
exist for active and secondhand tobacco smoke, occupa-
tional exposure to respiratory irritants and outdoor and
indoor air pollution.8
Smoking is the leading cause of COPD worldwide: 80e90%
of subjects diagnosed as COPD are long-term smokers
according to the American Lung Association. The cumulative
“dose” an individual smokes (unit amount per time of
smoking) can increase the probability of developing the
disease and intensify its severity. Quitting smoking can
prevent further lung damage. Besides direct smoking,
secondhand smoke exposure and occupational exposuresmay
also influence the development and the progression of the
disease and its health outcomes.8,9 Actually, it has been sug-
gestedthatanestimated25e45%ofpatientswithCOPDdonot
report a smoking history, suggesting a burden of non smoking
COPDwhichmaybehigher thanpreviouslybelieved.10About3
billion people, half the world’s population, are exposed to
smoke from biomass fuel compared with 1.01 billion who
smoke tobacco, which suggests that exposure to biomass
smoke might be the biggest risk factor for COPD globally.10
Byproducts of oxidative stress found in air pollutants
(ozone, sulfur oxides, carbonmonoxide, nitrogen oxides, and
particulate matter) are common initiators or promoters of
the damage produced in airways chronic diseases.
Since secondhand smoke is a modifiable risk factor,
clinicians, public health experts and politicians should
830 C.F. Donner et al.assess such exposure and counsel its avoidance. In public
health terms, the effects of secondhand smoke exposure on
susceptible subpopulations should provide a further ratio-
nale for laws prohibiting smoking in public.
In 2003 a systematic epidemiological review into occu-
pational factors associated with COPD by the American
Thoracic Society showed that about 15% of COPD cases
might be attributable to exposure to toxic gases in the
workplace, grain dust in farms, and dust and fumes in
factories.9 Use of appropriate protective devices (e.g. face
mask) in the workplace to avoid inhaling toxic or irritant
substances has been documented as potentially effective.
Exposure to indoor and outdoor air pollutants is a major
factor contributing to augment morbidity, healthcare
resources utilization and higher mortality among patients
with COPD, and largely impacting on public health, but
there are few studies on whether air pollution is a key
factor in the development of this disease.10
Strong evidence exists also for infections as a trigger of
COPD exacerbations. Prevention of respiratory infections,
such as influenza and pneumonia, can reduce the risk of
COPD worsening. Vaccinations can prevent some of the
infections that cause COPD exacerbations and should be
administered to all patients with COPD, although clinical
trial data are limited.11 Patient and physician barriers to
vaccination have to be overcome with targeted education
and system-wide interventions. In a large cohort of COPD
patients admitted to Italian hospitals for an exacerbation,
the percentage of subjects having received vaccination was
only 58% and 13% for influenza and pneumococcal vaccines,
respectively.6 More data on risk factors for COPD develop-
ment, progression and exacerbation, as well as on the role
and economic impact of commonly occurring comorbidities
(such as asthma), are in any case needed to implement
cost-effective prevention and management strategies.
Diagnosis
The diagnosis of COPD has been conventionally based on
spirometry and symptoms, in the presence of risk factors
such as smoking or occupational exposure.7 Adding medical
history data to spirometry is important as there is still much
underpresentation and underdiagnosis of COPD. Thus,
diagnostic guidelines should stress the importance of
persistent cough and phlegm to support timely diagnosis of
COPD in family practice.12
The GOLD Committee suggested the use of a fixed FEV1/
FVC cut-off of 0.70 instead of the more appropriate
statistically defined lower limit of normal. However,
according to a number of recent papers, the fixed cut-off of
0.70 significantly overestimates airflow obstruction in older
people leading to misuse of resources, and individual and
societal harm.13e15 On the other hand, it underestimates
airflow obstruction in young adults leading to a missed
opportunity for early diagnosis of COPD in patients who
might benefit from early intervention.13 Since diagnostic
confusion between COPD and asthma is common, bron-
chodilatation performed after spirometry can reduce the
likelihood of misclassifications in the presence of not-fully-
reversible airflow limitation.7
The complexity and heterogeneity of the disorders
encompassed by the term COPDwith the overlap of differentphenotypes have recently led to the following recommen-
dations: i) to develop a new taxonomy to better define the
disorders of airways obstruction and, consequently, ii) to
have amore multidimensional clinical assessment.16 Besides
FEV1/FVC, lung volumes should always be included in the
diagnosis of COPD as evaluation of hyperinflation can be an
important criterion to phenotype COPD.Treatment
Over the last two decades the previously nihilistic attitude
that smoking cessation was the only possible treatment for
COPD has changed to a more active approach. This is the
result of several large trials that investigated not only
pharmacological agents but also pulmonary rehabilitation
and lung volume reduction surgery. The current paradigm
holds that COPD is preventable and treatable.11,17 Despite
the valuable evidence-based data gained from these trials,
we have to bear in mind a limit: that the study populations
were highly selective, i.e. patients were only included if
they had COPD without concomitant morbidities which
could impact negatively on the trial outcomes. In real life,
however, COPD patients often have multiple, symptomatic
comorbidities, such as heart disease, osteoporosis,
peripheral muscle weakness and dysfunction, anemia,
depression, anxiety and lung cancer.18 Despite this,
patients receive treatment based on the trial results
whether they meet the basic inclusion/exclusion criteria or
not. As a consequence, the implementation of therapies on
a large scale requires a close monitoring of treatments as to
their safety and efficacy, thereby avoiding undue side
effects and negative consequences.
The pathophysiological hallmark of COPD is variable
airflow obstruction resulting in pulmonary hyperinflation.
The progressive decline in lung function leads to significant
limitations in daily life for patients with COPD over time,
which include dyspnea, exercise capacity, frequent exac-
erbations and hospitalizations.
Over the last several years, pharmacotherapy studies
have demonstrated that bronchodilators reduce dynamic
hyperinflation, increase inspiratory capacity (by reducing
the functional residual capacity), decrease work of
breathing, and improve ventilatory capacity during activity
and formal exercise testing. At a clinical level, bronchodi-
lators improve dyspnea, decrease exacerbations, amelio-
rate health-related quality of life (HRQoL) impairment, and
could possibly decrease mortality.7,17
Clinical studies with long-acting bronchodilators, long-
acting b2-agonists (LABA, such as formoterol, salmeterol
and more recently indacaterol) and long-acting anti-
muscarinic agents (tiotropium) have shown significant
improvements in trough peak FEV1 (range, 0.1e0.3 L) and
average FEV1 (range, 0.1e0.25 L) compared to a decline in
placebo-treated patients (short-acting b -agonists and/or
ipratropium). Comparable results were demonstrated with
FVC measurements.19,20 Clinical studies have evaluated the
use of a combination of tiotropium and long-acting b2-
agonists showing that there is a synergistic effect of the
combination therapy and further improvement in lung
function. This combination therapy will be suitable for
patients with severe disease.21
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these studies suggests that long-acting bronchodilators may
slow the decrease in lung function over time and subse-
quently change the clinical course of the disease.
Clinical studies using triple therapy e tiotropium and
fixed combination of long-acting b2 agonists and inhaled
corticosteroid e have demonstrated an enhanced improv-
ement in lung function, and a reduction of exacerbations as
compared with individual agents alone particularly in
patients with severe and very severe COPD.22
An unresolved question, namely whether regular treat-
ment with long-acting bronchodilators and/or the combi-
nation of LABA-inhaled corticosteroids should be initiated
at an earlier stage of the disease, remains to be answered.
Analyses of retrospectively identified subgroups from
TORCH and UPLIFT studies show that patients with
moderate disease might also benefit from these therapies,
with some evidence that there is a reduction in disease
progression. These studies showed significant increases in
some secondary endpoints which included trough FEV1,
peak FEV1, dyspnea score, and HRQoL. Notably, patients
also have a significant reduction in exacerbations.20
Recently there has been concern that the long-termuse of
inhaled bronchodilators commonly used in the treatment of
COPD, including long-acting b2-agonists and anticholinergic
drugs,may increase the risk of cardiovascular complications.
However, prospective data about the relative risk of therapy
in patients with sufficient symptoms to be eligible for
treatment is still lacking. The recent analysis of the tio-
tropium database and the findings of the UPLIFT study in fact
indicated a reduced mortality from cardiovascular events.
The mechanism by which tiotropium may reduce these
events and possibly improves survival could be associated
with the reductions in exacerbations and hospitalizations
observed. However, conclusive evidence is still lacking. In
the pooled analysis of 30 trials, tiotropium treatment resul-
ted in a reduction of serious cardiac adverse events.23
b2-agonists have the potential to precipitate cardiac
arrhythmias and other cardiac events; however, this has not
been regarded as important in clinical practice until
recently. In the TORCH study, patients randomised to LABA
alone had the lowest rate of cardiovascular death vs. those
who received placebo who had the highest rate. None of
the predicted risk factors for cardiovascular events (older
age, history of previous cardiac disease, worse lung func-
tion) interacted with treatment.24 However, this may not
reflect the real world situation since patients with relevant
cardiac comorbidities were excluded from these studies.
According to recent controlled randomized trials the risk
of pneumonia is increased in patients receiving inhaled
fluticasone. In the TORCH study, patients receiving at least
1000 mcg/day of fluticasone propionate equivalent
compared with non-users of inhaled corticosteroids within
the past year, had a rate ratio for pneumonia hospitaliza-
tion of 2.25 (95% CI 2.07e2.44). The TORCH trial showed no
difference in mortality from pneumonia between patients
on inhaled corticosteroids and those on placebo.25
The latest class of drugs introduced into COPD therapy are
selective phosphodiesterase-4 inhibitors. The recently EU-
approved, oral, once-daily PDE4 inhibitor, roflumilast, sup-
posedly targets airway inflammation. Participants in two
6-and12-month studies on roflumilastaloneor incombinationwith salmeterol and/or tiotropium had significant improve-
ments in lung function, quality of life and reduction in exac-
erbations. Adverse events were mostly mild in nature. The
twomost frequent in the roflumilast group were diarrhea and
weight loss.26
Follow up
COPD exacerbations frequently cause follow up or emer-
gency visits and hospitalizations and represent a major
financial challenge for most healthcare systems. A COPD
exacerbation has been defined as a change in the patient’s
baseline dyspnea, cough, and sputum beyond day-to-day
variations, with an acute onset, whichmaywarrant a change
in regular medication.11
Despite international guideline recommendations, the
management of COPDexacerbations varieswidely among the
different settings.6 Follow up modalities after hospitaliza-
tion to optimize care and reduce the risk of a relapse, the
recurrence of which is greatest within the first few weeks of
the initial event are even more diverse.27,28 Several risk
factors for a recurrent exacerbation have been identified:
number of previous exacerbations, previous hospitaliza-
tions, long-term use of oxygen, lung function, absence of a
primary caregiver andchoiceof pharmacological therapy.6,29
Specific recommendations for the management of patients
after anexacerbationare lacking. Further research is needed
to determine the most appropriate functional diagnosis and
severity stratification (e.g. spirometry is largely under-
used),6 the potential benefits of home monitoring and
noninvasive ventilation as well as the benefits of long-term
oxygen therapy in borderline respiratory failure, self-man-
agement programs and early rehabilitation.
Current guidelines recommend a followup 4e6weeks after
hospitalization where clinical status, inhaler technique, the
need for long-term oxygen therapy and FEV1 should be
assessed. Whether earlier timepoints after discharge reduce
exacerbations is unclear. There are few studies comparing the
effects of different frequencies of follow up visits on relapse
rates after hospitalization due to a COPD exacerbation.
Available data suggest that early rehabilitation should be
included in the follow up program as it reduces the hospi-
talization rates and improves exercise capacity and quality
of life.30 A large multicenter Italian study demonstrated
that only 14.5% of COPD patients admitted to hospital for an
exacerbation were offered pulmonary rehabilitation6 sug-
gesting that rehabilitation for COPD patients in different
healthcare settings requires improvement.
Long-term oxygen therapy (LTOT)
Oxygen therapy is essential in COPD patients with chronic
respiratory failure. Two prospective and randomized clinical
trialseNOTTandMRCepublished about 30 years ago31,32 are
today’s basis for prescribing oxygen therapy. In these studies
survival in stable COPD was improved with long-term oxygen
therapy (LTOT) for more than 15 h/day. Improvement in
survival has been documented only in COPD with severe
chronic hypoxemia (PaO2 < 55 mmHg (7.3 kPa) or PaO2
ranging from 56 to 59 mmHg (7.4e7.8 kPa) in the presence of
cor pulmonale, or a haematocrit of >55%).
832 C.F. Donner et al.The LTOT indications (based on NOTT and MRC) were
established in a very selected and limited number of patients
which might not represent the heterogeneity of the COPD
population. These recommendations have been subse-
quently extended, albeit without solid evidence, to COPD
patients with moderate hypoxemia (55 < PaO2 < 65 mmHg),
and to patients with a decreased oxygen saturation
(SaO2 < 90%) during exercise or sleep.
7,17,33 Comorbidities
are likely to affect both prognosis and health outcomes in
COPD patients but clinical guidelines do not provide
adequate guidance for patients on LTOT with complex
chronic diseases.
Prior to prescribing LTOT the COPD should be in a stable
phase. Unfortunately COPD patients frequently receive
home oxygen after an exacerbation, despite the absence of
data to support its short-term benefits. In fact, in up to 38%
of COPD PaO2 levels improved beyond those qualifying for
LTOT, simply by optimizing medical therapy.34 The reas-
sessment of the LTOT indication after 3 months of clinical
stability can significantly reduce the number of patients
requiring LTOT after an exacerbation.7,17 Given the incr-
easing numbers of patients receiving long-term supple-
mental oxygen, a critical revision of the actual indications
for LTOT is needed, particularly for COPD patients with
comorbidities, mild-moderate hypoxemia, exercise and
sleep desaturation. Also, given the high overall costs, LTOT
should be prescribed only for patients in whom there is a
reasonable expectation of clinical benefit.
Non-pharmacological therapies
The National Emphysema Trial (NETT) was the first rando-
mized trial in COPD in which a surgical procedure was
evaluated using a medical comparator, in this case optimal
medical therapy and pulmonary rehabilitation. In the
baseline evaluation and follow up of the patients included
in NETT, a very low FEV1 and diffusion capacity for carbon
monoxide (DLCO) were associated with a poor outcome.
35
These observations were important for defining the most
appropriate candidates for lung volume reduction.
Several trials have emphasized the benefits of pulmo-
nary rehabilitation with very little evidence regarding side
effects. The only drawback related to negative outcome is
that of patients who do not want to participate in reha-
bilitation or do not complete the program. The percentage
of patients who do not join programs is very high (around
60%) and out of those who join close to 30% fail to complete
the program. Very little has been done to better charac-
terize these patients and evaluate the factors that lead to
suboptimal compliance and adherence.36
Pharmacoeconomic issues
The cost of pharmacological treatment is steadily
increasing in all European countries. The main reasons are
expensive new hospital treatments with biological drugs
and cancer medications, and the progressive aging of the
population increasing the number of people with chronic
diseases including COPD.
Around the end of the last century a growing interest in
pharmacoeconomic issues corresponded to the overall needfor “accountability”, and the economic evaluation of oper-
ative strategies became the crucial point for decisionmakers
in allocating the diminishing healthcare resources. Although
pharmacoeconomic data are not easy to compare among the
different national health systems, the following examples
will show some common points, in particular: the very high
absolute and relative burden of COPD (despite substantial
underdiagnosis), the progressive increase of costs with
disease severity (the largest share of costs being due to
exacerbations and hospitalizations), the high proportion of
LTOT costs among overall therapy costs, the inadequate
coverage for drug expenses.The situation in North America
Canada
According to the BOLD survey37 the prevalence of COPD in
subjects aged 40 years or older in Canada is 11.1% (Stage I),
7.3% (Stage II) and 0.9% (Stage IIIeIV) or about 3.3 million,
considerably higher than the official estimate of 750,000
based on reported physician diagnosis.38
Primary care providers (PCP) and specialists are usually
paid on a fee-for-service basis. Consultation by specialists is
generally arranged through a PCP, because services for non-
referred patients are paid at a lower rate. The Canadian
RUSIC study39 estimated that exacerbations of COPD req-
uiring amedication change plus an outpatient visit (including
to an emergency department) had a mean cost of $641 (CAN
2006 $), whereas the mean cost of an exacerbation requiring
hospitalization was $9557. In 2003, the Confronting COPD
Survey estimated that the annual direct cost of COPD care
including laboratory tests and visits to PCPs and specialists,
was almost $2000 per patient, with about half of the costs
due to hospitalization.40 The estimated economic burden of
COPD through work loss was $1198 per patient, giving an
annual societal cost of $3195 per patient. Costs increased in
direct proportion to the severity of COPD as measured by
FEV1 or MRC dyspnea score.
There is no universal drug plan in Canada, and provincial
formularies act as barriers against the application of
current guidelines.
A survey of Canadian PCP practice patterns in COPD (CAGE
study) observed that only 34% of practices surveyed provided
treatment that matched guidelines.41 Non-prescription of
long-acting bronchodilators for patients with moderate and
severe COPD occurred in 27% and 21% of cases, resp., and
prescription of two long-acting bronchodilators for advanced
COPD occurred only in 49% of subjects.
The Canadian OPTIMAL trial42 demonstrated that triple
therapy with tiotropium þ fluticasone þ salmeterol was
superior to tiotropium þ salmeterol, or to tiotropium alone
in terms of lung function, frequency of exacerbations
requiring hospitalization and quality of life. A cost-effec-
tiveness analysis43 based on this trial demonstrated that the
incremental cost per exacerbation avoided with tiotro-
pium þ fluticasone þ salmeterol was $6510 (CAN) and the
incremental cost per quality adjusted life year (QUALY)
gained was $243,180 (CAN). The authors concluded that
neither tiotropium þ fluticasone þ salmeterol nor tiot-
ropium þ salmeterol seem economically attractive alterna-
tives compared with monotherapy with tiotropium for
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societal costperQUALYgainedandperexacerbationavoided.
Among non-pharmacologic therapies, pulmonary rehabili-
tation has undergone cost/benefit analysis in the Canadian
context.44 The cost for a 2-month inpatient followed by 4-
month outpatient programwas estimated at $11,597 (CAN) to
achieve clinically significant improvements in dyspnea,
emotional function, and mastery, with >90% of costs due to
the inpatient phase.44 A more recent study demonstrated
fewer hospitalizations when COPD patients completed
apulmonary rehabilitationprogram.45The valueandpotential
cost-effectiveness of developing smaller outpatient and
home-based rehabilitationprogramsshouldalsobestressed.46
The most significant gains in COPD healthcare utilization
may be realized through collaborative self-management
education.47 A Canadian randomized controlled trial
comparing case manager-driven self-management education
vs. usual care demonstrated a 40% reduction in the need for
COPD patients to access healthcare resources including
hospitalizations, emergency department visits and unsched-
uled clinic visits.48 Primary care is increasingly restructured
into multidisciplinary teams with financial incentives to
provide comprehensive care including certified respiratory
educators-facilitated self-management education.49
United States
COPD affects 20e24 million U.S. citizens, and is the 4th
leading cause of death with more than 125,000 deaths
annually. In 2010, the estimated direct healthcare costs of
COPD are $29.5 billion.50 Of these, $13.2 billion are due to
hospital care, $5.5 billion to physician costs, $5.8 billion to
outpatient prescription drug costs, $1.3 billion to home
healthcare costs, and $3.7 billion to nursing home care.
LTOT costs Medicare more than $2 billion per year for COPD
and the cost is growing by 12e18% per year.51 In addition,
there are $20.4 billion in indirect costs due to lost
productivity from death and disability.
The pharmacoeconomic evaluations of COPD have
recently been critically reviewed with generally concordant
results.52 Different studies have demonstrated that Ipra-
tropium in early stage COPD and a combination anticho-
linergic-b-agonist in more advanced COPD are associated
with lower overall healthcare costs, largely due to reduced
exacerbations requiring hospital care.53e55 These observa-
tional studies were supported by an economic analysis of
two clinical trials of ipratropium-albuterol combination
compared to ipratropium or albuterol alone.56 Both of the
ipratropium arms of the study indicated lower direct
healthcare costs than albuterol alone, mainly due to
a lower number of exacerbations and hospitalizations.
Long-acting b-agonists (LABA) or fluticasone as mono-
therapy can reduce COPD exacerbations which translates
into less healthcare costs.57,58 A clinical trial comparing
tiotropium to ipratropium demonstrated a 26% reduction in
exacerbations and 46% reduction in hospitalizations with
tiotropium. The cost-effectiveness of ICS was greater in the
most severely impaired individuals.59
Three economic analyses of the TORCH trial have been
published. In one study using the United States cost struc-
ture, salmeterol was the most cost-effective drug ($20,792/
QALY) followed by salmeterolefluticasone combinations
(SFC) ($33,865/QALY). Fluticasone alone was not consideredas cost-effective.60 A similar Markov-chain analysis of the
TORCH trial, using different cost assumptions, found that
SFC was the most cost-effective ($52,046/QALY), followed
by salmeterol monotherapy ($56,519/QALY) and fluticasone
monotherapy ($56,519).61 In a third analysis of TORCH, using
a multinational approach to cost structure, SFC was also
found to be most cost effective, compared to salmeterol or
fluticasone monotherapy. The cost-effectiveness was
considerably lower for SFC in the United States ($77,100/
QALY) compared to Western Europe ($24,200/QALY).62
A retrospective analysis of a Medicare database showed
that SFC was associated with slightly higher cost savings
than tiotropium ($110/year), and ipratropium-albuterol
($295/year), but fared substantially better than ipra-
tropium alone ($1235/year).62 There is also an economic
within trial analysis of exacerbation pivotal trials that
shows that SFC have an economic advantage in addition to
clinical efficacy in reducing exacerbations.63
The situation in Europe
Spain
In a recent population-based study the prevalence of COPD
in adults 40e70 years of age was 10.2%, with only 27% of
individuals with COPD having a previous diagnosis.64
Top-down studies reported COPD costs (both direct and
indirect) to be around €800 million annually in 1994. In
a microeconomic study performed in 1510 patients with
ambulatory COPD followed over one year (bottom-up),
the average annual costs per patient were $ 1876. In the
IBERPOC population-based epidemiological study, the
prevalence of COPD was estimated to be 9% in the 40e69
year age group, of which only 22% were diagnosed and
received treatment. Therefore, a total of 270,000 subjects
would be diagnosed and treated for COPD multiplied by the
annual average obtaining a total of $ 506.52 million annu-
ally in direct healthcare costs generated by COPD.
In a top-down calculation, hospital costs constituted
36.3% of the total, drug costs 42.2% and clinical consultations
and diagnostic tests 22.5%. In the study using the bottom-up
focus the hospital costs represented 43% of the total, drugs
40% and consultations and complementary tests 17%.
Thus, the distribution of the costs in these two studies
are similar and amount to an average of $13.32 annually for
each COPD patient.65e67
Scandinavia
The cost of COPD in Denmark amounts to 10% of all
healthcare costs. The annual costs for drugs in Scandinavia
is around €100 per inhabitant. The cost in Denmark rose
from about €2 billion in 2004 to €3 billion in 2008.68 This is
mainly covered by the public health system, some private
insurances and to a minor degree by patients. There are
large differences between regions in the prescribing
pattern of drugs with the same effect and side effect
profiles but in some cases a 10-fold difference in costs.
Italy
COPD costs were calculated in 2002 from data collected by
28 Lung Units within the framework of the National Health
Service (NHS). Mean cost/patient/year ranged from €1500
834 C.F. Donner et al.to 3912 according to severity. Direct costs, hospitalizations
and emergency room admissions in particular, represented
the main cost driver,69 with unacceptable levels for
underdiagnosis and mistreatment. Another investigation
reported the mean societal cost for COPD at €1308/p/y:
75% of the costs were due to hospitalizations.70 Investi-
gating via a Markov model the effectiveness of different
therapeutic interventions in outcome optimization, it was
found that both a prompt diagnosis of disease and exacer-
bations, together with an appropriate long-term thera-
peutic approach, represent the most effective strategy to
substantially reduce the impact of COPD on patient,
healthcare system and society.71
In 2008, health resources consumption and costs gener-
ated by COPD were calculated in a 1-year nation-wide,
bottom-up, observational, prospective multicenter study.
Outcomes were compared with those of the previous year.72
The proportion of moderate and severe COPD was 53.7 and
16.8%, respectively. Mean total costs/p/y were €2723.7,
ranging from 913 to 5452. At the end of the survey, require-
ment of health services had dropped significantly compared
to baseline: GP visits by 57.4%; Emergency Care use by 12.5%;
hospitalizations by 18.4%. The mean total cost per patient
dropped by 21.7% (p < 0.002), mainly due to a more appro-
priate interventional and therapeutic strategy. These data
show that the mean total costs/p/y of COPD doubled in a 5-
year period in Italy: the same trend has been registered in
other countries (such as USA) over the same period. Despite
this, and despite the fact that individual costs for COPD
exceedby67.7% themeanpercapitaexpensesof theNational
Health System, only about 20% of patients receive appro-
priate treatment for COPD. A recent cross-sectional study
supports the evidence that moderate COPD also represents
a substantial economic burden for healthcare systems.73
Role of the pulmonary specialist
Healthcare planning
An appropriate management of CRDs based on solid
epidemiological data requires a global approach defining
the best care for the patient throughout the course of the
disease, in a sustainable way for the community. Numerous
initiatives and studies have been launched. One of these is
the Global Alliance against chronic Respiratory Diseases
(GARD), an ensemble of national and international organi-
zations guided and coordinated by the World Health Orga-
nization (WHO). The role of the pulmonary specialist at
global and national level has been delineated within GARD’s
strategies and corresponding actions.74
GARD has formulated the following working
recommendations:
- To develop national programs of prevention and control
of CRDs, with the double aim of defining the most
pertinent strategies and healthcare actions and raising
political and social awareness about this public health
priority. The first step to attain this goal is health
education campaigns and data collection on: the fre-
quency of CRDs, their impact, and the relative risk
factors;- To provide training and continuing education on
prevention and treatment of CRDs, disseminating and
implementing the existing guidelines;
- To facilitate access to essential treatments and support
adherence to long-term management, including drug
treatment and pulmonary rehabilitation, particularly
amongst disadvantaged sectors of the population.
- Implementing healthcare strategies.
Patients affected by CRDs are managed in a discontin-
uous and non integrated mode with inappropriate care
procedures. Prevention, too is neither systematized nor
integrated. Inappropriateness costs both the individual and
the community. It has been calculated that GBP £1.3 billion
are spent each year in the U.K. for Emergency Care
admission (3e4 visits per patient) for a series of 18
diseases, COPD being at the top of the list and asthma in
third place. Varying percentages of these visits resulted not
appropriate at a retrospective analysis.75
An optimal management of CRDs should reduce the
crowding of Emergency Care facilities, global healthcare
costs, and improve patients’ quality of life. The long-term
goal must be to reduce the incidence of CRDs, while in a
shorter perspective the target is to reduce e in an
economically sustainable way e the social and economic
burden generated by those already affected, through
a greater appropriateness.
The specialist has a definite role to play in primary
prevention, early diagnosis and rehabilitation, as guide or
coordinator or consultant depending on the type of inter-
vention, in close cooperation with primary care, other
health professionals, and patient associations.
The interventions to promote are76:
1. To prevent CRDs developing through a consistent
reduction of the number of smokers in the community
and strict control of risk factors;
2. To improve and anticipate diagnosis, in particular for
COPD and asthma, through a more widespread use of
spirometry and specialist expertise;
3. To help patients self manage their own disease, through
health education and pulmonary rehabilitation;
4. To integrate the care of patients affected by CRDs,
through linking specialist care to primary care, and
extending end of life treatment to non-oncological
conditions.
In concrete terms, the specialist will build up a network
in which the Operational Unit functions as the junction for
the whole track of respiratory care, from primary preven-
tion to palliative care, according to the following scheme of
action:
- In primary prevention: implement smoking cessation,
increase the opportunity for screening for COPD and
associated conditions;
- In secondary prevention: increase accessibility to lung
function assessment, experiment screening models for
associated conditions, such as lung cancer;
- In improvement of patient management: further
reduce hospitalization through integration with services
Pharmacoeconomics in COPD 835in the local community, e.g. home hospitalization,
monitoring of patients with chronic respiratory failure,
health education, telemedicine; test a model of pulm-
onary rehabilitation provided in the local community;
expand and rationalize semi-intensive treatment;
promote the extension of palliative care to patients
with severe respiratory failure.
There is evidence that information and communication
technologies (ICT) can play an enabling role over the whole
range of services, from a better lifestyle and self-mana-
gement of health to improving HRQoL of patients as well as
managing chronic disease conditions.77 Properly designed
innovative health services supported by ICT might have
a positive impact on chronic disease modulation and prog-
nosis, shifting resources from traditional acute care to
integrated domiciliary long-term care, focusing on early
diagnosis and prevention of exacerbation, but they need to
be tested in clinical practice to verify if the cost/benefit
ratio is compatible with the current healthcare systems.
Adoption of ICT in healthcare is currently a major
priority in Europe as shown by the major e-health deploy-
ment initiatives (e.g. epSOS) launched through the
Competitiveness and Information Framework Program.78
To conclude, new studies on the pathogenesis, patho-
physiology, pharmacology of COPD will give new insight on
how to better classify and treat clinically a set of likely
different disorders with the same label. At the same time, it
is not redundant to remind that the real challenge for
a more appropriate approach to COPD in both an individual
and a social perspective is an innovative approach in the
frame of chronic healthcare, in which a patient-tailored
attitude should prevail over an old concept of a rigid health
system offering a very limited range of solutions to different
problems. Such a change has started, but it is still far from
meeting the minimal recommended standards.79 There is
large scope for quality improvement and the scientific
societies of pulmonary specialists can play a pivotal role in
implementing recommendations and developing research
for reliable performance measures that are necessary in the
quest for efficacy, efficiency and equity in the management
of COPD as of all other chronic disorders.
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